"Race for RSV Vaccines: Pfizer and GSK Face FDA Panel Review"

Pfizer and GlaxoSmithKline (GSK) are both racing to develop a vaccine for respiratory syncytial virus (RSV), a common respiratory illness that can cause severe symptoms in infants, older adults, and people with weakened immune systems. RSV is responsible for around 57,000 hospitalizations and up to 500 deaths in the United States each year.

Both Pfizer and GSK have submitted their respective RSV vaccine candidates for review by the US Food and Drug Administration (FDA). In October 2021, an FDA advisory committee will review the clinical data on these vaccines and make recommendations on their safety and efficacy.

Pfizer's RSV vaccine candidate, RSVpreF, uses a novel approach that involves using a small piece of the virus to stimulate an immune response. This approach is similar to the one used in Pfizer's highly effective COVID-19 vaccine, which has shown to be over 90% effective in preventing COVID-19 infection.

GSK's RSV vaccine candidate, GSK3844766A, uses a different approach, targeting a protein on the surface of the virus to stimulate an immune response. GSK's vaccine has been in development for several years and has undergone extensive testing in clinical trials.

If either Pfizer's or GSK's RSV vaccine candidate is approved by the FDA, it would mark a major breakthrough in the prevention of RSV. Currently, there are no approved vaccines for RSV, and treatment options are limited to supportive care, such as oxygen therapy and fluids.

However, the road to approval for RSV vaccines has been a long one. There have been several setbacks in the development of RSV vaccines over the years, including issues with vaccine-induced disease enhancement (VDE), a phenomenon where the immune response to the vaccine can actually worsen the disease in some cases.

RSV, which stands for respiratory syncytial virus, is a highly contagious respiratory illness that can cause severe symptoms in young children, older adults, and individuals with weakened immune systems. Currently, there is no approved vaccine for RSV, although several pharmaceutical companies are actively developing candidates.

Among the companies racing to develop an RSV vaccine are Pfizer and GlaxoSmithKline (GSK), both of whom are set to face FDA panel review. In October 2021, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to review Pfizer’s RSV vaccine candidate, while GSK’s candidate is set to be reviewed in November 2021.

Pfizer’s RSV vaccine candidate, which is called RSVpreF, uses a protein-based approach to stimulate an immune response against the virus. The candidate has already shown promising results in early-stage clinical trials, with one study showing that it was well-tolerated and induced a strong immune response in adults.

GSK’s RSV vaccine candidate, which is called GSK3888550A, also uses a protein-based approach to target the virus. The candidate is currently in phase 3 clinical trials, with interim data expected in the first half of 2022.

Despite the progress being made in RSV vaccine development, there are still several challenges that need to be overcome. For example, RSV is a complex virus with multiple strains, and it can be difficult to develop a vaccine that is effective against all of them. Additionally, RSV is known for its ability to evade the immune system, making it difficult to develop a long-lasting vaccine.

In addition to RSV, there are several other respiratory viruses for which there are no approved vaccines, including human metapneumovirus, parainfluenza virus, and adenovirus. As such, the development of effective vaccines for these viruses represents an important area of research and development for the pharmaceutical industry.

In conclusion, the race for an RSV vaccine is heating up, with Pfizer and GSK among the leading contenders. While there are still several challenges to be overcome, the development of an effective RSV vaccine would represent a major step forward in the fight against this highly contagious and potentially deadly virus.

Follow us on your favorite social platform for more!

Twitter

Youtube

Facebook